Application Nr Approved Date Route Status External Links
ANDA078917 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1. Indications And Usage Bicalutamide Tablets 50 Mg Daily Is Indicated For Use In Combination Therapy With A Luteinizing Hormone-Releasing Hormone (Lhrh) Analog For The Treatment Of Stage D 2 Metastatic Carcinoma Of The Prostate. Bicalutamide Tablets 150 Mg Daily Is Not Approved For Use Alone Or With Other Treatments [See Clinical Studies (14.2) ]. Bicalutamide Tablets 50 Mg Is An Androgen Receptor Inhibitor Indicated For Use In Combination Therapy With A Luteinizing Hormone-Releasing Hormone (Lhrh) Analog For The Treatment Of Stage D 2 Metastatic Carcinoma Of The Prostate. ( 1 ) Bicalutamide Tablets 150 Mg Daily Is Not Approved For Use Alone Or With Other Treatments. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Bicalutamide BICALUTAMIDE ZINC538564

Comments